National Institution for Occupational Safety and Health (NIOSH) Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), 31583 [E7-10987]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 109 / Thursday, June 7, 2007 / Notices
rwilkins on PROD1PC63 with NOTICES
Harmonized System of Classification
and Labeling of Chemicals (GHS), the
EPA, and the European Union hazard
classification systems. NICEATM and
ICCVAM prepared a comprehensive
background review document (BRD) on
each of the four in vitro test methods.
Each BRD included an analysis of test
method performance (i.e., reliability and
relevance) as compared to the in vivo
rabbit eye reference test method, based
on all available data. ICCVAM
developed recommendations on the
usefulness and limitations of these in
vitro test methods for identifying ocular
corrosives/severe irritants after
considering the BRDs, comments
received from the public and the
Scientific Advisory Committee on
Alternative Toxicological Methods
(SACATM), and comments and
recommendations received from an
independent expert panel (Federal
Register Vol. 70, No. 53, pp 13513–
13514, March 21, 2005 and Vol. 70, No.
211, p 66451, November 2, 2005).
ICCVAM is now reviewing the
validation status of these and other in
vitro test methods for identifying
nonsevere ocular irritants (i.e., those
that induce reversible ocular damage)
and non-irritants.
Request for Data
As part of the review process,
NICEATM requests the submission of
data from substances tested for ocular
irritancy in humans, rabbits, and/or in
vitro. Data received by July 23, 2007 will
be compiled and added to the database
maintained by NICEATM and utilized
where appropriate in the evaluation of
in vitro ocular irritation test methods.
Data received after this date will also be
considered and used where applicable
for future evaluation activities. All
information submitted in response to
this notice will be made publicly
available upon request to NICEATM.
When submitting substance and
protocol information/test data, please
reference this Federal Register notice
and provide appropriate contact
information (name, affiliation, mailing
address, phone, fax, e-mail, and
sponsoring organization, as applicable).
NICEATM prefers data to be
submitted as copies of pages from study
notebooks and/or study reports, if
available. Raw data and analyses
available in electronic format may also
be submitted. Each submission for a
substance should preferably include the
following information, as appropriate:
• Common and trade name.
• Chemical Abstracts Service Registry
Number (CASRN).
• Chemical and/or product class.
• Commercial source.
VerDate Aug<31>2005
20:59 Jun 06, 2007
Jkt 211001
• In vitro test protocol used.
• Rabbit eye test protocol used.
• Human eye test protocol used.
• Individual animal/human or in
vitro responses at each observation time
(i.e., raw data).
• The extent to which the study
complied with national/international
Good Laboratory Practice (GLP)
guidelines.
• Date and testing organization.
Additional information on the
submission of data may be obtained at
https://iccvam.niehs.nih.gov/methods/
ocutox/ivocutox.htm.
Background Information on ICCVAM
and NICEATM
ICCVAM is an interagency committee
composed of representatives from 15
federal regulatory and research agencies
that use or generate toxicological
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative methods with regulatory
applicability and promotes the scientific
validation and regulatory acceptance of
toxicological test methods that more
accurately assess the safety and hazards
of chemicals and products and that
refine, reduce, or replace animal use.
The ICCVAM Authorization Act of 2000
(42 U.S.C. 285l–3, available at https://
iccvam.niehs.nih.gov/docs/about_docs/
PL106545.pdf) established ICCVAM as a
permanent interagency committee of the
NIEHS under NICEATM. NICEATM
administers the ICCVAM and provides
scientific and operational support for
ICCVAM-related activities. NICEATM
and ICCVAM work collaboratively to
evaluate new and improved test
methods applicable to the needs of
federal agencies. Additional information
about ICCVAM and NICEATM is
available on the following Web site:
https://iccvam.niehs.nih.gov.
Dated: May 25, 2007.
Samuel H. Wilson,
Deputy Director, National Institute of
Environmental Health Sciences and National
Toxicology Program.
[FR Doc. E7–10966 Filed 6–6–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institution for Occupational
Safety and Health (NIOSH) Advisory
Board on Radiation and Worker Health
(ABRWH or Advisory Board)
Correction: This notice was published
in the Federal Register on May 22,
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
31583
2007, Volume 72, Number 98, pages
28697–28698. The meeting was
originally scheduled to be held at the
Westin Westminster Hotel. The
Committee will now convene at the
Sheraton Denver West Hotel, 360 Union
Boulevard, Lakewood, Colorado 80228,
Phone 303.987.2000, Fax 303.969.0263.
Times and Dates:
9 a.m.–5 p.m., June 11, 2007.
8 a.m.–3 p.m., June 12, 2007.
Contact Person for More Information:
Dr. Lewis V. Wade, Executive Secretary,
NIOSH, CDC, 4676 Columbia Parkway,
Cincinnati, Ohio 45226, Telephone
513.533.6825, Fax 513.533.6826.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: May 31, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office Centers for Disease Control
and Prevention.
[FR Doc. E7–10987 Filed 6–6–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004D–0466]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Substantiation for
Dietary Supplement Claims Made
Under the Federal Food, Drug, and
Cosmetic Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by July 9,
2007.
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974. All comments should be
ADDRESSES:
E:\FR\FM\07JNN1.SGM
07JNN1
]]>Agencies
[Federal Register Volume 72, Number 109 (Thursday, June 7, 2007)]
[Notices]
[Page 31583]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-10987]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Institution for Occupational Safety and Health (NIOSH)
Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board)
Correction: This notice was published in the Federal Register on
May 22, 2007, Volume 72, Number 98, pages 28697-28698. The meeting was
originally scheduled to be held at the Westin Westminster Hotel. The
Committee will now convene at the Sheraton Denver West Hotel, 360 Union
Boulevard, Lakewood, Colorado 80228, Phone 303.987.2000, Fax
303.969.0263.
Times and Dates:
9 a.m.-5 p.m., June 11, 2007.
8 a.m.-3 p.m., June 12, 2007.
Contact Person for More Information: Dr. Lewis V. Wade, Executive
Secretary, NIOSH, CDC, 4676 Columbia Parkway, Cincinnati, Ohio 45226,
Telephone 513.533.6825, Fax 513.533.6826.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both CDC and the Agency for Toxic Substances and Disease Registry.
Dated: May 31, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office Centers for
Disease Control and Prevention.
[FR Doc. E7-10987 Filed 6-6-07; 8:45 am]
BILLING CODE 4163-18-P
